Drug Profile


Alternative Names: BMS-477118; Onglyza; OPC-262

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer AstraZeneca; Bristol-Myers Squibb; Otsuka Pharmaceutical
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Dipeptides; Nitriles; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2017 Bristol-Myers Squibb and AstraZeneca completes a phase III trial for Type-2 diabetes mellitus (Combination therapy) in USA, Czech Republic, Denmark, Germany, Hungary, Mexico, Poland, Romania, South Africa, Spain and Sweden (PO) (NCT02551874)
  • 11 Oct 2017 Phase-III clinical trials in Type-2 diabetes mellitus (Combination therapy, In children, In adolescents) in USA, Poland, Finland (PO) (NCT03199053) (EudraCT2015-005042-66)
  • 03 Jul 2017 AstraZeneca plans a phase III trial for Type-2 diabetes mellitus (In children, In adolescents, Combination therapy) (PO) (NCT03199053)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top